Loading...

Jonathan Esensten, MD, PhD

TitleRES-FY
SchoolUCSF School of Medicine
DepartmentLaboratory Medicine
Address1700 4th St
San Francisco CA 94158
Phone415-514-9431
EmailJonathan.Esensten@ucsf.edu
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    University of California, San FranciscoM.D.2012 Medicine
    University of California, San FranciscoPh.D.2010 Graduate Division (Biomedical Sciences)
    University of California, San FranciscoResidency, Clinical Pathology2016Laboratory Medicine
    University of California, San FranciscoFellowship, Transfusion Medicine and Blood Banking2015Laboratory Medicine
    Collapse Awards and Honors
    University of California, San Francisco2016 - 2019Leukemia and Lymphoma Society Fellow
    San Francisco General Hospital2013 - 2013Krevans Award in Laboratory Medicine
    University of California, San Francisco2010 - 2010Alpha Omega Alpha Honor Society

    Collapse Overview 
    Collapse Overview
    Dr. Jonathan Esensten is a Leukemia and Lymphoma Society Fellow in the laboratory of Dr. Wendell Lim. His research is focused the development of synthetic and chemical biology approaches for T cell therapeutics. He is Medical Director of the UCSF HICTF and GMP Facility, which manufactures regulatory T cell products for clinical trials, among other cell therapy activities. He completed residency in clinical pathology and fellowship in transfusion medicine and blood banking at UCSF.


    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Esensten JH, Bluestone JA, Lim WA. Engineering Therapeutic T Cells: From Synthetic Biology to Clinical Trials. Annu Rev Pathol. 2016 Dec 05. PMID: 27959633.
      View in: PubMed
    2. Esensten JH, Helou YA, Chopra G, Weiss A, Bluestone JA. CD28 Costimulation: From Mechanism to Therapy. Immunity. 2016 May 17; 44(5):973-88. PMID: 27192564.
      View in: PubMed
    3. McCleland ML, Soukup TM, Liu SD, Esensten JH, de Sousa E Melo F, Yaylaoglu M, Warming S, Roose-Girma M, Firestein R. Cdk8 deletion in the Apc(Min) murine tumour model represses EZH2 activity and accelerates tumourigenesis. J Pathol. 2015 Dec; 237(4):508-19. PMID: 26235356.
      View in: PubMed
    4. Wiita AP, Hsu GW, Lu CM, Esensten JH, Wells JA. Circulating proteolytic signatures of chemotherapy-induced cell death in humans discovered by N-terminal labeling. Proc Natl Acad Sci U S A. 2014 May 27; 111(21):7594-9. PMID: 24821784; PMCID: PMC4040605.
    5. Martínez-Llordella M, Esensten JH, Bailey-Bucktrout SL, Lipsky RH, Marini A, Chen J, Mughal M, Mattson MP, Taub DD, Bluestone JA. CD28-inducible transcription factor DEC1 is required for efficient autoreactive CD4+ T cell response. J Exp Med. 2013 Jul 29; 210(8):1603-19. PMID: 23878307; PMCID: PMC3727315.
    6. de Kouchkovsky D, Esensten JH, Rosenthal WL, Morar MM, Bluestone JA, Jeker LT. microRNA-17-92 regulates IL-10 production by regulatory T cells and control of experimental autoimmune encephalomyelitis. J Immunol. 2013 Aug 15; 191(4):1594-605. PMID: 23858035; PMCID: PMC4160833.
    7. Bour-Jordan H, Esensten JH, Martinez-Llordella M, Penaranda C, Stumpf M, Bluestone JA. Intrinsic and extrinsic control of peripheral T-cell tolerance by costimulatory molecules of the CD28/?B7 family. Immunol Rev. 2011 May; 241(1):180-205. PMID: 21488898; PMCID: PMC3077803.
    8. McClymont SA, Putnam AL, Lee MR, Esensten JH, Liu W, Hulme MA, Hoffmüller U, Baron U, Olek S, Bluestone JA, Brusko TM. Plasticity of human regulatory T cells in healthy subjects and patients with type 1 diabetes. J Immunol. 2011 Apr 1; 186(7):3918-26. PMID: 21368230; PMCID: PMC3091943.
    9. Esensten JH, Wofsy D, Bluestone JA. Regulatory T cells as therapeutic targets in rheumatoid arthritis. Nat Rev Rheumatol. 2009 Oct; 5(10):560-5. PMID: 19798031; PMCID: PMC3086064.
    10. Esensten JH, Lee MR, Glimcher LH, Bluestone JA. T-bet-deficient NOD mice are protected from diabetes due to defects in both T cell and innate immune system function. J Immunol. 2009 Jul 1; 183(1):75-82. PMID: 19535634; PMCID: PMC2732575.
    11. Esensten JH, Tsytsykova AV, Lopez-Rodriguez C, Ligeiro FA, Rao A, Goldfeld AE. NFAT5 binds to the TNF promoter distinctly from NFATp, c, 3 and 4, and activates TNF transcription during hypertonic stress alone. Nucleic Acids Res. 2005; 33(12):3845-54. PMID: 16027109; PMCID: PMC1175021.
    Jonathan's Networks
    Concepts
    Derived automatically from this person's publications.
    _
    Co-Authors
    People in Profiles who have published with this person.
    _
    Related Authors
    People who share related concepts with this person.
    _
    Back to TOP